par Barst, Robyn J.;Langleben, David;Badesch, David B.;Frost, Adaani;Lawrence, E Clinton;Shapiro, Shelley;Naeije, Robert
;Galie, Nazzareno;STRIDE-2 Study Group,
Référence Journal of the American College of Cardiology, 47, 10, page (2049-2056)
Publication Publié, 2006-05

Référence Journal of the American College of Cardiology, 47, 10, page (2049-2056)
Publication Publié, 2006-05
Article révisé par les pairs
Résumé : | We sought to determine the optimal dose of the selective endothelin A (ET(A)) receptor antagonist sitaxsentan for the treatment of pulmonary arterial hypertension (PAH); for observation only, an open-label (OL) bosentan arm was included. |